Evidence map›Paper›PMID 35296317›Full record

ArticleBMC complementary medicine and therapies2022

Chrysoeriol suppresses hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes and inhibits JAK2/STAT3 signaling.

Jia-Ying Wu, Ying-Jie Chen, Xiu-Qiong Fu, Jun-Kui Li, Ji-Yao Chou, Cheng-Le Yin, Jing-Xuan Bai, Ying Wu, Xiao-Qi Wang, Amy Sze-Man Li and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Frontiers in microbiology · 2026
    Article
  3. Article
  4. A CCL5Cell & bioscience · 2025
    Article
  5. Article
  6. Review
  7. Pharmacological Activities ofMolecules (Basel, Switzerland) · 2024
    Review
  8. Article
  9. Review
  10. Nutrients · 2023
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Jia-Ying Wu *Research and Development Centre for Natural Health Products, HKBU Shenzhen Institute of Research and Continuing Education, Shenzhen, China.
Ying-Jie Chen *Research and Development Centre for Natural Health Products, HKBU Shenzhen Institute of Research and Continuing Education, Shenzhen, China.
Xiu-Qiong FuResearch and Development Centre for Natural Health Products, HKBU Shenzhen Institute of Research and Continuing Education, Shenzhen, China.
Jun-Kui LiResearch and Development Centre for Natural Health Products, HKBU Shenzhen Institute of Research and Continuing Education, Shenzhen, China.
Ji-Yao ChouResearch and Development Centre for Natural Health Products, HKBU Shenzhen Institute of Research and Continuing Education, Shenzhen, China.
Cheng-Le YinResearch and Development Centre for Natural Health Products, HKBU Shenzhen Institute of Research and Continuing Education, Shenzhen, China.
Jing-Xuan BaiResearch and Development Centre for Natural Health Products, HKBU Shenzhen Institute of Research and Continuing Education, Shenzhen, China.
Ying WuResearch and Development Centre for Natural Health Products, HKBU Shenzhen Institute of Research and Continuing Education, Shenzhen, China.
Xiao-Qi WangResearch and Development Centre for Natural Health Products, HKBU Shenzhen Institute of Research and Continuing Education, Shenzhen, China.
Amy Sze-Man LiResearch and Development Centre for Natural Health Products, HKBU Shenzhen Institute of Research and Continuing Education, Shenzhen, China.
Lut Yi WongResearch and Development Centre for Natural Health Products, HKBU Shenzhen Institute of Research and Continuing Education, Shenzhen, China.
Zhi-Ling YuResearch and Development Centre for Natural Health Products, HKBU Shenzhen Institute of Research and Continuing Education, Shenzhen, China. zlyu@hkbu.edu.hk.
Hong Kong Baptist University · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFibroblast-like synoviocytes (FLS) have cancer cell-like characteristics, such as abnormal proliferation and resistance to apoptosis, and play a pathogenic role in rheumatoid arthritis (RA). Hyperproliferation of RA-FLS that can be triggered by the activation of interleukin-6/signal transducer and activator of transcription 3 (IL-6/STAT3) signaling destructs cartilage and bone in RA patients. Chrysoeriol is a flavone found in medicinal herbs such as Chrysanthemi Indici Flos (the dried capitulum of Chrysanthemum indicum L.). These herbs are commonly used in treating RA. Chrysoeriol has been shown to exert anti-inflammatory effects and inhibit STAT3 signaling in our previous studies. This study aimed to determine whether chrysoeriol inhibits hyperproliferation of RA-FLS, and whether inhibiting STAT3 signaling is one of the underlying mechanisms.

methodsIL-6/soluble IL-6 receptor (IL-6/sIL-6R)-stimulated RA-FLS were used to evaluate the effects of chrysoeriol. CCK-8 assay and crystal violet staining were used to examine cell proliferation. Annexin V-FITC/PI double staining was used to detect cell apoptosis. Western blotting was employed to determine protein levels.

resultsChrysoeriol suppressed hyperproliferation of, and evoked apoptosis in, IL-6/sIL-6R-stimulated RA-FLS. The apoptotic effect of chrysoeriol was verified by its ability to cleave caspase-3 and caspase-9. Mechanistic studies revealed that chrysoeriol inhibited activation/phosphorylation of Janus kinase 2 (JAK2, Tyr1007/1008) and STAT3 (Tyr705); decreased STAT3 nuclear level and down-regulated protein levels of Bcl-2 and Mcl-1 that are transcriptionally regulated by STAT3. Over-activation of STAT3 significantly diminished anti-proliferative effects of chrysoeriol in IL-6/sIL-6R-stimulated RA-FLS.

conclusionsWe for the first time demonstrated that chrysoeriol suppresses hyperproliferation of RA-FLS, and suppression of JAK2/STAT3 signaling contributes to the underlying mechanisms. This study provides pharmacological and chemical justifications for the traditional use of chrysoeriol-containing herbs in treating RA, and provides a pharmacological basis for developing chrysoeriol into a novel anti-RA agent.

Indexed as

Arthritis, RheumatoidFlavonesSynoviocytesFibroblastsHumansJanus Kinase 2STAT3 Transcription FactorchrysoeriolFlavonesJAK2 protein, humanJanus Kinase 2STAT3 protein, humanSTAT3 Transcription FactorApoptosisChrysoeriolJAK2ProliferationRheumatoid arthritis fibroblast-like synoviocytesSTAT3 signaling

Identifiers

PMID35296317
PMCPMC8928618
OpenAlexW4220662689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.